NCT05577845

5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 212 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

Conditions

• LARS - Low Anterior Resection Syndrome

Interventions

Type	Name	Description
DRUG	Ramosetron	Ramosetron, 4 weeks

Timeline

• Start date: 2023-03-27
• Primary completion: 2025-12-01
• Completion: 2032-12-01
• First posted: 2022-10-13
• Last updated: 2023-04-25

Locations

1 site across 1 country: South Korea